PMID: 22548830

Hegedus C, Truta-Feles K, Antalffy G, Varady G, Nemet K, Ozvegy-Laczka C, Keri G, Orfi L, Szakacs G, Settleman J, Varadi A, Sarkadi B
Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.
Biochem Pharmacol. 2012 Aug 1;84(3):260-7. Epub 2012 Apr 21., [PubMed]
Sentences
No. Mutations Sentence Comment
174 ABCG2 p.Arg482Gly
X
ABCG2 p.Arg482Gly 22548830:174:131
status: NEW
view ABCG2 p.Arg482Gly details
 In contrast, until now the issue of conferring vandetanib resistance has only been addressed using the clinically irrelevant ABCG2 R482G variant [42], and to the best of our knowledge, this is also the first report analyzing ABCG2- interaction profiles of the other two novel EGFR inhibitors, pelitinib or neratinib. Login to comment 180 ABCG2 p.Arg482Gly
X
ABCG2 p.Arg482Gly 22548830:180:131
status: NEW
view ABCG2 p.Arg482Gly details
 In contrast, until now the issue of conferring vandetanib resistance has only been addressed using the clinically irrelevant ABCG2 R482G variant [42], and to the best of our knowledge, this is also the first report analyzing ABCG2- interaction profiles of the other two novel EGFR inhibitors, pelitinib or neratinib. Login to comment